GlassScriptPhysician profile
Faisal Hayat
NPI 1336354653
$2,892.45
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,919 · 2021: $421 · 2022: $487 · 2023: $66.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,362.23 | 2019 | |
| Shockwave Medical, INC | $531.24 | 2021-2022 | |
| Abbott Laboratories | $346.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $276.84 | 2019-2022 | |
| Abiomed | $81.39 | 2019-2023 | Impella |
| Amgen INC. | $49.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.42 | 2019 | |
| Cardiovascular Systems INC. | $27.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.09 | 2019 | |
| Bardy Diagnostics, INC. | $25.00 | 2019 | |
| Chiesi USA, INC. | $22.49 | 2019 | |
| Elutia, INC. | $21.41 | 2019 | |
| Biotronik INC. | $20.99 | 2019 | |
| Angiodynamics, INC. | $15.16 | 2021 | |
| Amarin Pharma, INC. | $13.39 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $13.29 | 2019 | |
| Medtronic, INC. | $11.06 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Hayat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.